Genzyme’s Asian Expertise Drives Alnylam Co-Development Pact For TTR Candidates

RNAi pioneer Alnylam is partnering its transthyretin-mediated amyloidosis program with Genzyme in Japan and Asia-Pacific, while planning to keep rest-of-world rights to the program in-house.